Indeed, AURK inhibitors are known to be active against MTC [31, 32] and synergy between AURKs and FLT3 is currently being explored clinically through a number of dual-AURKB/FLT3 inhibitors [33, 34]. The gene discussed is AURKB; the disease is medullary thyroid gland carcinoma.